Busulfan /kg

Phase 1Small molecule

MMemorial Sloan Kettering Cancer Center

Busulfan /kg is one of 11 small molecule programs targeting Hematologic Malignancies. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hematologic MalignanciesActive, not recruiting

Hematologic MalignanciesPhase 1

Active, not recruiting

Competition

Competitive Landscape

14 competitors in Hematologic Malignancies

#DrugCompanyPhaseTrials

Cellcept

Roche

Phase 2

21 2

Cytoxan

BBaxter Healthcare Corporation

Phase 2

27 3

Prograf

VVeloxis Pharmaceuticals

Phase 2

18 4

Jakafi

Incyte

Phase 2

1 5

Fludara

Sanofi

Phase 1

20 6

Alkeran

AApotex Inc.

Phase 1

14 7

Rapamune

PPrism Pharmaceuticals

Phase 1

5 8

Antithymocyte Globulin

Sanofi

Phase 1

3 9

Venclexta

AbbVie

Preclinical

7 10

Vidaza

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 1Active, not recruiting

Hematologic Malignancies

NCT04098393

Clinical

Trials by Indication[1]

Hematologic Malignancies1 trial

A Pilot Study of Condensed Busulfan, Melphalan, and Fludarabine Conditioning Prior to Ex-vivo CD34+ Selected Allogeneic Hematopoietic Cell Transplantation

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT04098393·39 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Busulfan /kg. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Busulfan /kg compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Busulfan /kg. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Memorial Sloan Kettering Cancer Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: MMemorial Sloan Kettering Cancer Center

Busulfan /kg

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Trials by Indication[1]

Hematologic Malignancies1 trial

References

Drug Info

Quick Facts

Related News